2,358
Participants
Start Date
May 2, 2024
Primary Completion Date
November 30, 2025
Study Completion Date
April 30, 2026
Hecolin® (Recombinant Hepatitis E Vaccine (Escherichia coli)).
Hecolin® will be administered 2 doses administered 4 weeks apart during pregnancy and 1 dose administered after delivery at least 20 weeks following the second dose for the pregnant participants (arm 1), and 0, 1 and 6 months for the non-pregnant participant (arm 3).
Isotonic Sodium Chloride injection
Placebo will be administered 2 doses administered 4 weeks apart during pregnancy and 1 dose administered after delivery at least 20 weeks following the second dose for the pregnant participants (arm 2)
RECRUITING
The Aga Khan University, Karachi
Open Philanthropy
OTHER
Bill and Melinda Gates Foundation
OTHER
Thrasher Research Fund
OTHER
International Vaccine Institute
OTHER